Target intelligence / Profile preview

Foot-and-Mouth Disease Virus non-neutralizing capsid epitopes and nonstructural proteins (FMDV NSPs and non-neutralizing epitopes)

Target
FMDV NSPs and non-neutralizing epitopes
Molecular classification
Viral protein, Enzyme, Structural protein, RNA-dependent RNA polymerase, Cysteine protease
01

Overview

Foot-and-Mouth Disease Virus (FMDV) non-neutralizing capsid epitopes and nonstructural proteins (NSPs) are essential components in the study and management of FMD, a highly contagious viral disease affecting cloven-hoofed animals. While the viral capsid consists of four structural proteins (VP1, VP2, VP3, and VP4) that contain the primary neutralizing epitopes for vaccine-induced protection, the NSPs (such as 3ABC, 3D, 2C, and 3C) are expressed only during active viral replication. This distinction is the basis for the Differentiating Infected from Vaccinated Animals (DIVA) strategy, where the presence of antibodies against NSPs like 3ABC indicates a natural infection rather than vaccination with purified, inactivated virus. Biologically, these NSPs are responsible for critical viral processes, including the 3C protease-mediated cleavage of the viral polyprotein and the 3D polymerase-mediated replication of the RNA genome. Non-neutralizing epitopes on the capsid also contribute to the overall immune landscape and can be targets for diagnostic assays. Understanding these targets is vital for developing effective veterinary vaccines and robust surveillance tools to prevent the economic devastation associated with FMD outbreaks.

Other names
FMDV non-structural proteinsFMDV NSPs3ABC proteinFMDV non-neutralizing antigensFoot-and-mouth disease virus polyprotein
02

Mechanism of action

Induction of humoral and cellular immune responses for prophylaxis; diagnostic differentiation of infected from vaccinated animals (DIVA); inhibition of viral polyprotein cleavage or RNA replication.

03

Biological functions

Viral replicationPolyprotein processingImmune responseHost cell modulationViral assemblyRNA synthesis
04

Disease associations

InfectionFoot-and-mouth disease
05

Safety considerations

Antigenic drift and serotype diversity (O, A, C, SAT 1-3, Asia 1)Risk of incomplete vaccine inactivationDiagnostic cross-reactivityShort-lived immunity
06

Interacting drugs

Inactivated Foot-and-Mouth Disease Virus Vaccine

2 more in the full profile.

07

Biomarkers

Anti-3ABC antibodiesAnti-2C antibodiesAnti-3D antibodiesFMDV RNA

Beyond the preview

Go deeper on Foot-and-Mouth Disease Virus non-neutralizing capsid epitopes and nonstructural proteins (FMDV NSPs and non-neutralizing epitopes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foot-and-Mouth Disease Virus non-neutralizing capsid epitopes and nonstructural proteins (FMDV NSPs and non-neutralizing epitopes).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call